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Résumé en
anglais
Circadian timing largely modifies efficacy and toxicity of many anticancer drugs.
Recent findings suggest that optimal circadian delivery patterns depend on the
patient genetic background. We present here a combined experimental and
mathematical approach for the design of chronomodulated administration schedules
tailored to the patient molecular profile. As a proof of concept we optimized
exposure of Caco-2 colon cancer cells to irinotecan (CPT11), a cytotoxic drug
approved for the treatment of colorectal cancer. CPT11 was bioactivated into SN38
and its efflux was mediated by ATP-Binding-Cassette (ABC) transporters in Caco-2
cells. After cell synchronization with a serum shock defining Circadian Time (CT) 0,
circadian rhythms with a period of 26 h 50 (SD 63 min) were observed in the mRNA
expression of clock genes REV-ERBα, PER2, BMAL1, the drug target topoisomerase
1 (TOP1), the activation enzyme carboxylesterase 2 (CES2), the deactivation enzyme
UDP-glucuronosyltransferase 1, polypeptide A1 (UGT1A1), and efflux transporters
ABCB1, ABCC1, ABCC2 and ABCG2. DNA-bound TOP1 protein amount in presence
of CPT11, a marker of the drug PD, also displayed circadian variations. A
mathematical model of CPT11 molecular pharmacokinetics-pharmacodynamics (PK-
PD) was designed and fitted to experimental data. It predicted that CPT11
bioactivation was the main determinant of CPT11 PD circadian rhythm. We then
adopted the therapeutics strategy of maximizing efficacy in non-synchronized cells,
considered as cancer cells, under a constraint of maximum toxicity in synchronized
cells, representing healthy ones. We considered exposure schemes in the form of an
initial concentration of CPT11 given at a particular CT, over a duration ranging from
1 to 27 h. For any dose of CPT11, optimal exposure durations varied from 3h40 to
7h10. Optimal schemes started between CT2h10 and CT2h30, a time interval
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